New research suggests that people who discontinue popular GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass at a significantly accelerated pace than those who end traditional diet and exercise programs.
Findings released in a major health publication demonstrates that while obese people can lose a large proportion of their total mass while undergoing treatment, the weight is regained at an estimated rate of nearly a kilo each month once they quit.
"People using these medications should be cognizant of the potential of fast rebound weight gain when the treatment concludes," warns expert Dr. Susan Jebb.
That rate of regain suggests a return to original weight within about 18 months.
Weighing Treatments
The study, which looked at dozens of trials involving over 9,000 of participants, contrasted the effects of GLP-1 agonists with conventional dieting.
Researchers note that people who lose weight through dieting usually see a less rapid creep back—perhaps 100 grams monthly—post-intervention.
Explaining the Rapid Regain
Experts propose the mode of action of the jabs accounts for the accelerated weight return.
These medications copy a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Sustained high doses of the hormone levels far above than the body's typical production may cause the system to generate a reduced amount of its own natural GLP-1, and may also reduce sensitivity to its actions," noted Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this medication means hunger is no longer kept in check, making binge eating much more probable."
A Lifelong Condition?
The NHS suggest the injections for individuals with obesity-related health risks, accompanied by recommended diet and exercise modifications.
Professionals contend that, considering the significant potential of weight regain, the treatment should be considered ongoing.
This view is supported by pharmaceutical companies, who say that the findings "emphasize the long-term nature of excess weight," comparing it to managing conditions like high blood pressure.
User Accounts
Individuals who have come off the jabs describe a intense return of hunger.
"I experienced a trigger activating and I was suddenly extremely hungry," described an individual.
This difficulty is exacerbated if users have not adopted permanent dietary or behavioural changes during therapy.
Significant Use
Survey data indicate that millions of people in the UK have used these injections in the last 12 months, with demand remaining high.
- Use is higher among females than men.
- The middle-aged age group shows the greatest level of interest.
- Many obtain the drugs through private prescriptions rather than the NHS.
Finally, experts emphasize that while these medications are potent agents for shedding pounds, they are not a permanent cure and maintained weight loss hinges on combined lifestyle management.